These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 21599617

  • 1. Investigational antibody drug conjugates for solid tumors.
    Sapra P, Hooper AT, O'Donnell CJ, Gerber HP.
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
    [Abstract] [Full Text] [Related]

  • 2. The next generation of antibody-drug conjugates comes of age.
    Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N.
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [Abstract] [Full Text] [Related]

  • 3. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L, Benhar I.
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody-based therapies in cancer: advances and challenges.
    Sapra P, Shor B.
    Pharmacol Ther; 2013 Jun; 138(3):452-69. PubMed ID: 23507041
    [Abstract] [Full Text] [Related]

  • 5. Challenges in the development and manufacturing of antibody-drug conjugates.
    Ducry L.
    Methods Mol Biol; 2012 Jun; 899():489-97. PubMed ID: 22735971
    [Abstract] [Full Text] [Related]

  • 6. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J.
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE, Cotreau M, Han TH, Gupta M.
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [Abstract] [Full Text] [Related]

  • 10. Designing immunoconjugates for cancer therapy.
    Govindan SV, Goldenberg DM.
    Expert Opin Biol Ther; 2012 Jul; 12(7):873-90. PubMed ID: 22679911
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH.
    Life Sci; 2024 Jun 15; 347():122676. PubMed ID: 38688384
    [Abstract] [Full Text] [Related]

  • 13. Immunoconjugates against solid tumors: mind the gap.
    Ricart AD.
    Clin Pharmacol Ther; 2011 Apr 15; 89(4):513-23. PubMed ID: 21368753
    [Abstract] [Full Text] [Related]

  • 14. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.
    Ann N Y Acad Sci; 2014 Aug 15; 1321():41-54. PubMed ID: 25123209
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antibody drug conjugates.
    Bakhtiar R.
    Biotechnol Lett; 2016 Oct 15; 38(10):1655-64. PubMed ID: 27334710
    [Abstract] [Full Text] [Related]

  • 17. The next generation of antibody drug conjugates.
    Mack F, Ritchie M, Sapra P.
    Semin Oncol; 2014 Oct 15; 41(5):637-52. PubMed ID: 25440608
    [Abstract] [Full Text] [Related]

  • 18. Naptumomab estafenatox: a new immunoconjugate.
    Robinson MK, Alpaugh RK, Borghaei H.
    Expert Opin Biol Ther; 2010 Feb 15; 10(2):273-9. PubMed ID: 20053143
    [Abstract] [Full Text] [Related]

  • 19. [Design of next generation antibody drug conjugates].
    Zhu GD, Fu YX.
    Yao Xue Xue Bao; 2013 Jul 15; 48(7):1053-70. PubMed ID: 24133971
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.